SPEX - スフェリクス (Spherix Incorporated)

SPEXのニュース

   The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index  2020/03/10 13:19:55 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.
   3 Biotech Stocks Defying Today's Market Meltdown Thanks To COVID-19 Developments  2020/03/09 17:30:09 Benzinga
The major U.S. stock market averages were all tumbling close to 5% and bond yields were hitting record lows Monday following oil's plunge in the wake of the wrangling between Saudi Arabia and Russia. Yet biotechs with a connection to the fight against COVID-19 were turning in yet another stellar performance. Spherix Spearheads Gains Spherix Inc (NASDAQ: SPEX ), which rose to prominence Friday with an announcement concerning an exclusive option agreement with the University of Maryland, Baltimore, for a technology to treat coronavirus infection, is building on the momentum. After ending Friday's session higher by more than 130%, Spherix shares were trading up by a … Full story available on Benzinga.com
   4 Biotech Stocks Moving On COVID-19 Updates  2020/03/06 20:48:25 Benzinga
The COVID-19 outbreak has proved to be a catalyst for biotechs. Some issues that were wallowing in penny stock territory have posted stratospheric gains in the wake of efforts to develop diagnostic tests, treatments and vaccines to combat the new coronavirus. Here are four stocks that were moving in Friday's session on coronavirus-related news: Spherix Inc (NASDAQ: SPEX ) Spherix said it has executed an exclusive option agreement with the University of Maryland Baltimore for the technology covered by a patent entitled "Methods of Treating Coronavirus Infection." The invention was made with aid from the National Institute of Health. Under the option, Spherix has until the end of May 2020 to complete due diligence and execute a license agreement for commercial development. Enzo Biochem, Inc. (NYSE: ENZ ) The diagnostic company said its … Full story available on Benzinga.com
   Spherix stock soars after option executed for technology in patent for methods to treat coronavirus infection  2020/03/06 15:09:00 Yahoo Finance
Shares of Spherix Inc. soared 21% in active morning trading Friday, after the biotechnology company said it executed an exclusive option agreement with the University of Maryland, Baltimore for the technology in the patent for "Methods of Treating Coronavirus Infection." Trading volume swelled to 2.2 million shares, already more than the full-day average of 1.2 million shares. The company said the invention was made with support awarded by the National Institutes of Health, which has certain rights in the invention. Under terms of the option, Spherix said it has until the end of May to execute a license agreement for commercial development. The stock has lost 23% over the past three months, while the iShares Nasdaq Biotechnology ETF has slipped 2.5% and the S&P 500 has shed 6.9%.
   Spherix to become AIkido Pharma  2020/03/05 20:57:38 Seeking Alpha
Effective March 13, Spherix (SPEX -12.8%) will change its name to AIkido Pharma Inc. Shares will trade under the ticker "AIKI." The company says the new mo
   Spherix Attends Artificial Intelligence and Machine Learning Pharmaceutical Development Conference  2020/02/25 15:00:00 PR Newswire
NEW YORK, Feb. 25, 2020 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced its attendance at the AI & ML Drug Discovery Summit. The AI-ML in Drug Development Summit is the only conference to bring together industry leaders, technology experts and academics focused on…
   Spherix Issues Letter to Shareholders  2020/02/14 14:00:00 PR Newswire
NEW YORK, Feb. 14, 2020 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX), a technology development company committed to the fostering of innovative ideas, today issued a letter to shareholders: Dear Fellow Shareholder, One of the most important responsibilities of a public company CEO…
   Spherix files for equity offering; shares down 11% after hours  2020/01/31 21:37:56 Seeking Alpha
Thinly traded nano cap Spherix (NASDAQ:SPEX) slips 11% after hours in response to its preliminary prospectus for a $5.75M stock offering. Price, volume and
   Spherix Launches Newly Redesigned Website  2020/01/21 15:00:00 PR Newswire
NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that it has redesigned the company's website (www.spherix.com) to illuminate the overall digital transformation and recently acquired anti-cancer therapeutics. The new digital platform will…
   Promising Early Launch Metrics for AbbVie's Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights  2019/12/16 19:14:00 Benzinga Feeds
EXTON, Pa. , Dec. 16, 2019 /PRNewswire/ -- Spherix examined the charts of 1,021 rheumatoid arthritis (RA) patients recently switched from one biologic/JAK to another agent via the 2019 annual RealWorld Dynamix™: Biologic/JAK Switching in Rheumatoid Arthritis (US) service. The patient chart analysis revealed that TNF inhibitor cycling remains the most common switch pattern among RA patients, though has leveled off over the past year after steady decreases since 2016. Nevertheless, the percent of patients being switched from one TNF inhibitor to another drops with each line of biologic/JAK therapy, as rheumatologists are more inclined to prescribe an alternate mechanism agent in the second- or later-line setting. While the percent of patients being switched to a TNF inhibitor stands unchanged from the prior year, switches to JAK inhibitors have increased in popularity – likely at the expense of the IL-6 inhibitor class, which had been experiencing year over year gains in the switch- to segment up until the current year (reverting back to figures reported in 2016).
   Spherix Launches Newly Redesigned Website  2020/01/21 15:00:00 PR Newswire
NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that it has redesigned the company's website (www.spherix.com) to illuminate the overall digital transformation and recently acquired anti-cancer therapeutics. The new digital platform will…
   Promising Early Launch Metrics for AbbVie's Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights  2019/12/16 19:14:00 Benzinga Feeds
EXTON, Pa. , Dec. 16, 2019 /PRNewswire/ -- Spherix examined the charts of 1,021 rheumatoid arthritis (RA) patients recently switched from one biologic/JAK to another agent via the 2019 annual RealWorld Dynamix™: Biologic/JAK Switching in Rheumatoid Arthritis (US) service. The patient chart analysis revealed that TNF inhibitor cycling remains the most common switch pattern among RA patients, though has leveled off over the past year after steady decreases since 2016. Nevertheless, the percent of patients being switched from one TNF inhibitor to another drops with each line of biologic/JAK therapy, as rheumatologists are more inclined to prescribe an alternate mechanism agent in the second- or later-line setting. While the percent of patients being switched to a TNF inhibitor stands unchanged from the prior year, switches to JAK inhibitors have increased in popularity – likely at the expense of the IL-6 inhibitor class, which had been experiencing year over year gains in the switch- to segment up until the current year (reverting back to figures reported in 2016).
   Spherix Announces the Closing of CBM BioPharma Transaction  2019/12/10 15:00:00 PR Newswire
NEW YORK, Dec. 10, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that it has closed the CBM BioPharma, Inc. transaction and is working to develop these cancer drugs. Building on its successful investment in Hoth Therapeutics, Inc., Spherix now owns a diverse…
   Spherix Notes Additional Patent Coverage Granted  2019/11/27 19:59:00 PR Newswire
NEW YORK, Nov. 27, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) announced today that additional patent coverage has been granted by the United States Patent & Trademark Office to the patent portfolio being acquired by Spherix, in the field of pancreatic cancer. Pancreatic…
   Spherix Highlights ValuEngine Upgrade to 'Buy' Rating  2019/10/17 12:30:00 ACI Information Group
NEW YORK , Oct. 17, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that its stock has been upgraded to a "buy" rating from a "hold" rating in a research note …

calendar